GSK To Spend Up to $1.56B for Rights to Potential COVID-19, Flu Vaccines [Yahoo! Finance]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance
GSK said it will pay CureVac as much as $1.56 billion to assume full control of the treatments. The companies have been working together on mRNA vaccines since 2020. Drug maker GSK ( GSK ) agreed to pay up to $1.56 billion for the rights to develop, manufacture, and market COVID-19 and influenza vaccines being worked on in collaboration with German biotechnology company CureVac ( CVAC GSK said CureVac would receive EUR400 million ($432 million) up front, and up to an additional EUR1.05 billion ($1.13 billion) in development, regulatory, and sales milestones. The companies teamed up during the COVID-19 outbreak in 2020 to create mRNA vaccines for infectious diseases. GSK said its efforts have produced “candidates for seasonal influenza and COVID-19 in phase II and avian influenza in phase I clinical development” based on CureVac's mRNA technology. The updated deal means GSK will “assume full control of developing and manufacturing these candidate vaccines," the company said.
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNAAccesswire
- Arbutus Biopharma: Focused On HBV With A Potentially Huge Litigation 'Wildcard' [Seeking Alpha]Seeking Alpha
- U.S. Government Awards Moderna $176 Million Bird Flu Vaccine Contract [zero hedge]zero hedge
- Does H5N1 avian influenza have pandemic potential? [Yahoo! Finance]Yahoo! Finance
- Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More [Yahoo! Finance]Yahoo! Finance
MRNA
Earnings
- 5/2/24 - Beat
MRNA
Sec Filings
- 6/28/24 - Form 4
- 6/26/24 - Form 144
- 6/21/24 - Form 4
- MRNA's page on the SEC website